Could It Be? Another Covid Variant Spreading Through The U.S.?

Just when we thought we were getting Covid under control, yet another variant of the virus is getting attention as it spreads through multiple countries. Covid Delta variant AY.4.2, also known as “Delta Plus,” has been found throughout the United Kingdom, and has now been spotted in labs in at least 8 different states in the U.S. Health authorities are doing extensive research to find out just why this variant is spreading faster than other variants, as well as if the current vaccines are effective against this new strain.

The AY.4.2 Delta Variantblue virus cells of all different sizes with a delta symbol in the middle

The AY.4.2 variant is a sub-lineage of the variant AY.4, and was first detected at the end of September, though it appears it surfaced in the UK around June. The U.K. has recorded one of the highest numbers of new Covid cases in any country in the past 30 days, second to the U.S.; the U.S., though, has so far only recorded 11 cases of the new variant, in California, Florida, Maryland, Massachusetts, Nevada, North Carolina, Rhode Island and Washington state (as well as the District of Columbia). So far, it appears that Delta Plus spreads faster than other variants, with some scientists estimating that AY.4.2 has a 10-15% transmission advantage over Delta. They have noted, though, that it does not appear to cause more severe illness. 

“We have teams that are constantly reviewing the genetic sequence data and looking for blips, an increase in a certain proportion or just something that’s completely new,” says Dr. Summer Galloway, executive secretary of the U.S. government’s SARS-CoV-2 Interagency Group. 

Will The Current Vaccine Suffice?

Health authorities believe that current vaccines do remain effective against the new Covid strain AY.4.2. It’s still too early to tell just how much of an impact this new variant will have on Americans, but health officials point out that it takes higher levels of population immunity from both vaccinations and past infections to slow down transmission, no matter which variant we are dealing with. 

“Right now, I think there’s not a lot that we know. But in terms of the risk that it poses to public health, the prevalence is very low in the U.S. and we don’t really anticipate that the substitutions [of AY.4.2] are going to have a significant impact on either the effectiveness of our vaccines or its susceptibility to monoclonal antibody treatments,” said Galloway.needle and vial with covid-19 vaccine on the labelProf. Gupta, a member of the New and Emerging Respiratory Virus Threats Advisory Group, which advises the U.K. government, suggests that Delta is more contagious than previous variants because it can infect vaccinated people, who then pass it to other people. He says that “The high speed of replication means that the vaccinated person gets an infection and can spread it. Therefore, masks are an essential component of mitigation.”

It is still too early to tell how much of an impact the new Covid variant will have on the country, but researchers are closely monitoring this development to make sure we do not have another wave/surge in cases. Health officials are also hopeful that more people will continue to get vaccinated, because, as they point out, the more people get the shot, the better the chances of minimizing the new variant’s effects.

Will You Need Booster Shots? Moderna Tests Vaccine Longevity.

The Covid-19 vaccines have been available in the U.S. for around 9 months, and researchers are continuing to study their effectiveness, specifically questioning how long the protection they offer will actually last. And now, a recent analysis conducted by Moderna, who makes one of the two mRNA Covid-19 vaccines, has shown that the effectiveness of the vaccine decreases as time goes by. In fact, according to the study, people who got the shot last year are twice as likely to contract the virus as people who recently got the shot. Moderna is hoping that this new data will lead to approval of a third-dose booster shot for those who received the original two-shot dose.

The Study

illustration of a woman in a lab coat looking through a microscope

The trial conducted over the summer by Moderna, labeled the 3 COVE Study, compared participants who received the vaccine between July 1, 2021 and August 27, 2021 to participants who got it between July 2020 and October 2020. Analysis of the data revealed that people who had recently received the vaccine had a lower risk of breakthrough infection than people who had been vaccinated last year. Specifically, “88 breakthrough cases of COVID-19 out of 11,431 people vaccinated occurred in the more recently vaccinated group (49.0 cases per 1000 person-years) compared to 162 cases out of 14,746 participants in the group vaccinated last year (77.1 cases per 1000 person-years).”

The study found that people who were vaccinated last year had a 50% higher rate of symptomatic breakthrough cases during the months of July and August compared to those who had received the vaccination later. And of those who received the vaccine more recently, there were no hospitalizations or deaths, compared to the 3 Covid-19 related hospitalizations of the earlier group, which resulted in 2 deaths.

“There’s a large debate, we all know, about whether or not vaccine boosters are going to be necessary in the fall,” Moderna President Stephen Hoge said. “That debate, what makes it really hard is it’s not really about whether the vaccine worked last month. It’s really about whether it’s going to work this winter.”

Is There a Need For A Booster Shot?

When the study and its data was presented, Moderna CEO Staphane Bancel stated that it proves the need for a booster shot. person receiving a shot in their arm

“It is promising to see clinical and real-world evidence adding to the growing body of data on the effectiveness of the Moderna COVID-19 vaccine,” Bancel said. “The increased risk of breakthrough infections in COVE study participants who were vaccinated last year compared to more recently illustrates the impact of waning immunity and supports the need for a booster to maintain high levels of protection.”

Currently, the White House’s plan is for people to get a third dose 8 months after their second shot of either the Pfizer or Moderna vaccine. However, multiple scientists from the World Health Organization and 2 FDA officials claim it is “not appropriate” to widely distribute booster shots to the general public just yet.